These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
145 related items for PubMed ID: 23915009
1. Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer. Fujiwara K, Nagao S, Aotani E, Hasegawa K. Expert Opin Pharmacother; 2013 Sep; 14(13):1797-806. PubMed ID: 23915009 [Abstract] [Full Text] [Related]
2. [Intraperitoneal chemotherapy for ovarian cancer]. Noma J, Yoshida N. Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214 [Abstract] [Full Text] [Related]
3. Carboplatin versus cisplatin in ovarian cancer. Alberts DS. Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869 [Abstract] [Full Text] [Related]
4. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer? Petignat P, du Bois A, Bruchim I, Fink D, Provencher DM. Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887 [Abstract] [Full Text] [Related]
5. Systemic therapy for ovarian cancer: current status and new treatments. Ozols RF. Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797 [Abstract] [Full Text] [Related]
7. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166 [No Abstract] [Full Text] [Related]
8. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Thigpen T, Vance R, Puneky L, Khansur T. Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816 [Abstract] [Full Text] [Related]
11. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Fujiwara K, Armstrong D, Morgan M, Markman M. Int J Gynecol Cancer; 2007 Dec; 17(1):1-20. PubMed ID: 17291226 [Abstract] [Full Text] [Related]
12. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents. Ozols RF. J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247 [Abstract] [Full Text] [Related]
13. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Ozols RF. Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787 [Abstract] [Full Text] [Related]
14. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL, Meisner BC, Armstrong DK, Frick KD. Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927 [Abstract] [Full Text] [Related]
15. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie. du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C. Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296 [Abstract] [Full Text] [Related]
16. The role of intraperitoneal chemotherapy in ovarian cancer. Markman M. Clin Adv Hematol Oncol; 2006 Nov; 4(11):809-10. PubMed ID: 17143249 [No Abstract] [Full Text] [Related]
18. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. Forum (Genova); 2000 Mar; 10(4):323-32. PubMed ID: 11535983 [Abstract] [Full Text] [Related]
19. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Harper P. Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217 [Abstract] [Full Text] [Related]